Nathan Bryson

Nathan Bryson, PhD, is the Chief Scientific Officer at Reunion Neuroscience, an early stage pharmaceutical company developing new molecules to treat mental health conditions. Throughout their career, Nathan has held various leadership positions in pharmaceutical companies such as Field Trip Health, Acerus Pharma, Cynapsus Therapeutics, Cannasat Therapeutics, Matregen, and Bionisis. With a strong educational background including a PhD in Chemistry from Massachusetts Institute of Technology, Nathan has extensive experience in drug development, formulation, and research management.